PMID- 28428285 OWN - NLM STAT- MEDLINE DCOM- 20171107 LR - 20191210 IS - 1472-4146 (Electronic) IS - 0021-9746 (Linking) VI - 70 IP - 11 DP - 2017 Nov TI - Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. PG - 926-934 LID - 10.1136/jclinpath-2016-204137 [doi] AB - AIMS: GATA-binding protein 3 (GATA3) is a sensitive and relatively specific marker in breast and urothelial carcinomas. Its diagnostic utility in primary and metastatic breast cancers has been explored and confirmed. However, the relationship between GATA3 expression and different breast carcinoma intrinsic subtypes has not been specifically defined in the literature despite a few reports with a small number of cases. The aim of the current investigation is to clarify GATA3 expression among different histological subtypes and surrogate molecular breast carcinoma subtypes in a large series of cases. METHODS: Immunohistochemical staining of GATA3, GCDFP15 and mammaglobin was performed in a cohort of 1637 cases of primary invasive breast carcinoma. The association of GATA3 expression with different histological and surrogate intrinsic subtypes was assessed and compared with the expression of GCDFP15 and mammaglobin. RESULTS: The overall positivity of GATA3 across the various immunohistochemistry-based surrogate intrinsic subtypes was 99.51% for luminal A-like, 97.70% for luminal B-like, 68.50% for HER2 overexpression and 20.16% for triple negative breast cancers. GATA3 expression was positively correlated with estrogen receptor (ER)-positive (luminal subtypes) breast carcinomas. For luminal-like and HER2 overexpression subtypes, GATA3 was much more sensitive than GCDFP15 and mammaglobin. For triple negative tumours, GATA3 was less sensitive than GCDFP15. CONCLUSIONS: GATA3 exhibits a relatively high sensitivity for breast carcinomas. It is more sensitive than GCDFP15 and mammaglobin in luminal-like and HER2 overexpression subtypes. GATA3 expression is associated with breast carcinomas of luminal subtype and low histological grade. CI - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. FAU - Shaoxian, Tang AU - Shaoxian T AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Baohua, Yu AU - Baohua Y AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Xiaoli, Xu AU - Xiaoli X AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Yufan, Cheng AU - Yufan C AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Xiaoyu, Tu AU - Xiaoyu T AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Hongfen, Lu AU - Hongfen L AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Rui, Bi AU - Rui B AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Xiangjie, Sun AU - Xiangjie S AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Ruohong, Shui AU - Ruohong S AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. FAU - Wentao, Yang AU - Wentao Y AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. AD - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. LA - eng PT - Comparative Study PT - Journal Article DEP - 20170420 PL - England TA - J Clin Pathol JT - Journal of clinical pathology JID - 0376601 RN - 0 (Biomarkers, Tumor) RN - 0 (Carrier Proteins) RN - 0 (GATA3 Transcription Factor) RN - 0 (GATA3 protein, human) RN - 0 (Glycoproteins) RN - 0 (Membrane Transport Proteins) RN - 0 (PIP protein, human) RN - 0 (Secretoglobins) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biomarkers, Tumor/*analysis MH - Biopsy MH - Breast Neoplasms/*chemistry/classification/pathology MH - Carcinoma/*chemistry/classification/pathology MH - Carrier Proteins/analysis MH - Diagnosis, Differential MH - Female MH - GATA3 Transcription Factor/*analysis MH - Glycoproteins/analysis MH - Humans MH - *Immunohistochemistry MH - Membrane Transport Proteins MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Invasiveness MH - Predictive Value of Tests MH - Receptor, ErbB-2/analysis MH - Secretoglobins/analysis MH - Young Adult OTO - NOTNLM OT - BREAST OT - CARCINOMA OT - IMMUNOHISTOCHEMISTRY COIS- Competing interests: None declared. EDAT- 2017/04/22 06:00 MHDA- 2017/11/08 06:00 CRDT- 2017/04/22 06:00 PHST- 2016/09/20 00:00 [received] PHST- 2017/03/17 00:00 [revised] PHST- 2017/03/19 00:00 [accepted] PHST- 2017/04/22 06:00 [pubmed] PHST- 2017/11/08 06:00 [medline] PHST- 2017/04/22 06:00 [entrez] AID - jclinpath-2016-204137 [pii] AID - 10.1136/jclinpath-2016-204137 [doi] PST - ppublish SO - J Clin Pathol. 2017 Nov;70(11):926-934. doi: 10.1136/jclinpath-2016-204137. Epub 2017 Apr 20.